A deeptech startup from Osaka University in the healthcare and pre‐symptomatic field, At visualizes pre‐symptomatic disease using a capillary scope.
Milestone
At will complete mass production of its autofocus capillary scope in 2025 to exhibit at the Osaka Kansai Expo. In 2026 they aim to establish a lifestyle-related disease risk assessment system, expanding with the goal of an IPO in 2028.